{"id":104,"date":"2024-11-15T10:00:00","date_gmt":"2024-11-15T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=104"},"modified":"2025-09-09T06:23:22","modified_gmt":"2025-09-09T06:23:22","slug":"china-bd-deal-2024-lanova-and-msd-enters-a-3-3-billion-usd-license-on-pd-1-vegf-bsabs-lm-299","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/104.html","title":{"rendered":"[China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1\/VEGF BsAbs LM-299"},"content":{"rendered":"\n<p>Announced Date: 2024-11-14 (November 14, 2024)<\/p>\n\n\n\n<p>Asset Name: LM-299<\/p>\n\n\n\n<p>Licensor: LaNova Medicines Ltd. (LaNova) (China)<\/p>\n\n\n\n<p>Licensee (Buyer): MSD (tradename of Merck &amp; Co., Inc., USA)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: BsAbs (Bispecific antibody)<\/p>\n\n\n\n<p>Asset Target: PD-1 and VEGF (Programmed cell death protein-1, Vascular endothelial growth factor)<\/p>\n\n\n\n<p>Current Stage: China phase 1\u00a0;<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>LaNova has granted MSD an exclusive global license to develop, manufacture and commercialize LM-299.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$588 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$2.7 billion,<\/p>\n\n\n\n<p>Total $3.288 billion plus.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.msd.com\/news\/msd-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd\/\">MSD Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1\/VEGF Bispecific Antibody from LaNova Medicines Ltd. &#8211; MSD<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.msd.com\/news\/msd-closes-exclusive-global-license-agreement-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody\/\">MSD Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1\/VEGF Bispecific Antibody &#8211; MSD<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-11-14 (November 14, 2024) Asset Name: LM-299 Licensor: LaNova Medicines Ltd. (LaNova) (China) Licensee &hellip; <a title=\"[China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1\/VEGF BsAbs LM-299\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/104.html\"><span class=\"screen-reader-text\">[China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1\/VEGF BsAbs LM-299<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-104","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=104"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/104\/revisions"}],"predecessor-version":[{"id":268,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/104\/revisions\/268"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}